Please Wait
Applying Filters...
menu
    • menu
    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Suanfarma, at the Core of a Better Life.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-03-23

    Virtual Booth

    An Enquiry

    Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-03-23

    Virtual Booth

    An Enquiry

    Menu

    ONL1204

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    ONL Therapeutics Starts Global Phase 2 GALAXY Trial
    ONL Therapeutics Starts Global Phase 2 GALAXY Trial

    16 Mar 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/onl-therapeutics-announces-first-european-patient-randomized-in-its-global-phase-2-galaxy-trial-of-xelafaslatide-onl1204-in-patients-with-geographic-atrophy-ga-associated-with-dry-amd-302714650.html

    PR NEWSWIRE
    16 Mar 2026
    Share Share
    ONL Therapeutics Publishes Phase 1B Data On Xelafaslatide
    ONL Therapeutics Publishes Phase 1B Data On Xelafaslatide

    09 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/09/3202198/0/en/ONL-Therapeutics-Announces-Publication-of-Data-from-Phase-1b-Study-of-Xelafaslatide-an-Investigational-Therapy-for-Geographic-Atrophy-in-Ophthalmology-Science.html

    GLOBENEWSWIRE
    09 Dec 2025
    Share Share
    ONL Therapeutics Starts Global Phase 2 GALAXY Trial of ONL1204
    ONL Therapeutics Starts Global Phase 2 GALAXY Trial of ONL1204

    28 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/28/3175222/0/en/ONL-Therapeutics-Announces-Randomization-of-First-Patient-in-Global-Phase-2-GALAXY-Trial-of-Xelafaslatide-ONL1204-in-Patients-with-Geographic-Atrophy-GA-Associated-with-Dry-AMD.html

    GLOBENEWSWIRE
    28 Oct 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.